Because high expression of CCND1 was reported to be associated with poor prognosis in a subset of ER-positive breast cancer patients [23], we assume that BNAT1 silencing may be applied to alternative therapeutic options for endocrine-resistant breast cancers through the inhibition of the CCND1-dependent cell proliferation pathway. The gene discussed is BNAT1; the disease is breast carcinoma.